Market Newsdesk

DALLAS, Dec. 10, 2020 /PRNewswire/ — In advance of the Climate Ambition Summit this Saturday, December 12, marking the fifth anniversary of the Paris Agreement, Jacobs (NYSE:J) has fulfilled its commitment to transition to 100% renewable energy for its operations in 2020 and achieved net-zero carbon emissions for its operations and business travel in 2020. These milestones and other key objectives were outlined earlier this year in Jacobs’ first Climate Action Plan to help address the climate crisis.

Jacobs has also published carbon reduction targets to cover Scope 3 (indirect emissions) and these have been approved by the Science Based Target Initiative.

“Reaching our goal to become carbon neutral is a major step in improving the way we run our operations at Jacobs,” said Jacobs Chair and CEO Steve Demetriou. “And our biggest opportunity to affect climate change is through the work performed for our clients – helping them to achieve change and create a better tomorrow for all. Together, we are pushing the limits of what is possible and staying ahead to create the new standards of our future.”

Jacobs achieved carbon neutrality for its operations and business travel in 2020, in line with global standard PAS 2060:2014, by reducing its carbon consumption and neutralizing remaining carbon impact by purchasing renewable energy and carbon offsets. Jacobs anticipates that its renewable energy and carbon offset purchases will diminish each year as it continually reduces its direct and indirect emissions. Jacobs is also committed to becoming carbon negative for its operations and business travel by 2030.

Joining over 300 companies worldwide, Jacobs has also signed the United Nations (UN) Business Ambition for 1.5°C – an urgent request for action from the global coalition of UN agencies, business and industry leaders, calling on businesses to set ambitious science-based emissions reduction targets aligned with limiting global temperature rise to 1.5°C above pre-industrial levels.

Last month, Jacobs launched its own Pledge to Action campaign inviting partners from across the globe to pledge their own tailored, measurable climate action commitments. And in their efforts to continue to drive the climate agenda, Jacobs is supporting five key clients to undertake a climate-risk assessment to better understand climate-related vulnerabilities and aid decision making.

For more information on how Jacobs is working to address climate change for a brighter tomorrow, visit jacobs.com/climate-action-plan.

At Jacobs, we’re challenging today to reinvent tomorrow by solving the world’s most critical problems for thriving cities, resilient environments, mission-critical outcomes, operational advancement, scientific discovery and cutting-edge manufacturing, turning abstract ideas into realities that transform the world for good. With approximately $14 billion in revenue and a talent force of more than 55,000, Jacobs provides a full spectrum of professional services including consulting, technical, scientific and project delivery for the government and private sector. Visit jacobs.com and connect with Jacobs on Facebook, Instagram, LinkedIn and Twitter

Certain statements contained in this press release constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are intended to be covered by the safe harbor provided by the same. Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements, including, but not limited to, the impact of the COVID-19 pandemic and the related reaction of governments on global and regional market conditions and the company’s business. For a description of some additional factors that may occur that could cause actual results to differ from our forward-looking statements, see our Annual Report on Form 10-K for the year ended October 2, 2020, and in particular the discussions contained under Item 1 – Business; Item 1A – Risk Factors; Item 3 – Legal Proceedings; and Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations, as well as the company’s other filings with the Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.

For press/media inquiries:
Kerrie Sparks
214.583.8433

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/jacobs-achieves-net-zero-carbon-emissions-and-100-renewable-energy-301190085.html

SOURCE Jacobs

NEW YORK, Dec. 10, 2020 /PRNewswire/ — Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Minerva Neurosciences, Inc. (“Minerva” or the “Company”) (NASDAQ: NERV) from May 15, 2017 through November 30, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the District of Massachusetts alleges violations of the Securities Exchange Act of 1934.

If you purchased Minerva securities, and/or would like to discuss your legal rights and options please visit Minerva Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the “end-of-Phase 2” meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company’s plan to use the combination of the Phase 2b and Phase 3 studies would be “highly unlikely” to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to “substantial review issues” because the trials were inadequate and not well-controlled; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times

On December 1, 2020, Minerva issued a press release in which the Company announced the outcome of tis Type C Meeting with the FDA concerning roluperidone.  In the announcement, Minerva stated that it had “received official meeting minutes from the November 10, 2020 Type C meeting with the” FDA.  In  this release, Minerva disclosed for the first time that the “”FDA advised that the Phase 2b study is problematic because it did not use the commercial formulation of roluperidone and was conducted solely outside of the United States. In addition, FDA commented that the Phase 3 study does not appear to be capable of supporting substantial evidence of effectiveness . . . .” Indeed, the “FDA cautioned that an NDA submission based on the current data from the Phase 2b and Phase 3 studies would be highly unlikely to be filed and that at a minimum, there would be substantial review issues due to the lack of two adequate and well-controlled trials to support efficacy claims for this indication.”

On this news, Minerva’s stock price fell from its November 30, 2020 closing price of $3.89 per share to a December 1, 2020 closing price of $2.89 per share.

If you wish to serve as lead plaintiff, you must move the Court no later than February 8, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Minerva securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/minervaneurosciencesinc-nerv-shareholder-class-action-lawsuit-stock-fraud-342/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero

Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/nerv-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-class-action-lawsuit-has-been-filed-against-minerva-neurosciences-inc-301190090.html

SOURCE Bernstein Liebhard LLP

STOCKHOLM, Dec. 10, 2020 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announced that a Marketing Authorization Application for emapalumab has been accepted for review in China. The targeted indication is for treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.

“Today’s announcement marks an important step for those affected by primary HLH, as currently there are no approved treatments available in China to meet the vast unmet medical need for this life threatening condition,” said Ravi Rao, Head of Research & Development and Chief Medical Officer at Sobi. 

About primary HLH

Primary HLH is a rare syndrome that typically presents in infancy but can also be seen in adults and is associated with high morbidity and mortality. In spite of some treatment advances, there continues to be a very high unmet medical need in particular in patients that have failed conventional therapy as there are no approved treatment options outside the US. In the US, emapalumab is the first therapy approved by the US Food & Drug Administration (FDA) for primary HLH. Over 100 patients have been treated in the US and the benefit/risk profile continues to be favourable.

About emapalumab

Emapalumab is a monoclonal antibody that binds to and neutralises interferon gamma (IFNγ). In the US, emapalumab is indicated for the treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Primary HLH is a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. The FDA approval is based on data from the phase 2/3 studies (NCT01818492 and NCT02069899). Emapalumab is indicated for administration through intravenous infusion over one hour twice per week until haematopoietic stem cell transplantation (HSCT). For more information please see www.gamifant.com including the full US Prescribing Information. In September 2020, emapalumab received Orphan Drug Designation (ODD) by the FDA for prevention of graft failure following haematopoietic stem cell transplantation.

About Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi’s revenues amounted to SEK 14.2 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

For more information please contact

Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
[email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/emapalumab-submission-in-china-for-primary-hlh,c3251558

The following files are available for download:

 

View original content:http://www.prnewswire.com/news-releases/emapalumab-submission-in-china-for-primary-hlh-301190141.html

SOURCE Swedish Orphan Biovitrum AB

BEIJING, Dec. 10, 2020 /PRNewswire/ — iQIYI Inc. (NASDAQ: IQ) (“iQIYI” or the “Company”), an innovative market-leading online entertainment service in China, held its annual signature iQIYI Scream Night 2021 online on December 5 and 6. During the event, the Company handed out 40 honorary awards across various categories, from drama and variety shows, to music and film, recognizing outstanding performers and high-quality content seen across iQIYI’s entertainment landscape in 2020.

Thanks to iQIYI’s keen insights of the entertainment industry and its thorough analysis of users’ requirement for entertainment, Scream Night has become a bellwether in the entertainment industry.

In the drama category, a number of iQIYI-produced series were honored with awards. The Bad Kids, a short suspense drama from the widely acclaimed Mist Theater content library, won “Blockbuster Drama Series of the Year” while other Mist theater series made it into the “Top 10 Drama Series of the Year.” In the variety show category, Youth with You Season 2, won “Variety Show of the Year”. The Rap of China 2020 and I’m CZR Season 2 won “IP-based Variety Shows of the Year”,  with musicians Kris Wu, Zhou Yan (aka GAI), and Switch GodLes respectively awarded as “Singer-Songwriter of the Year”, “Rapper of the Year” and “New Singer of the Year.”

Scream Night 2021 also featured a movie section. Huang Bo, Shen Teng, Peng Yuchang and other actors received awards for their brilliant performances in movies such as My People, My Homeland, Leap, The Eight Hundred and The Sacrifice. Director, Guan Hu was awarded “Director of the Year.”

Over the last few years, iQIYI has focused on building up its own IP-centered content ecosystem, covering a range of entertainment genres such as movies, dramas, variety shows, animation, literature and interactive content.

At a time when users’ demands become more fragmented and diversified, the entertainment industry should analyze data to accurately match users’ preference with their content feed. To this end, iQIYI implements a more detailed categorization of its content to cater to a wider group of audience.

For example, “Mist Theater”, is a fine-tuned collection of dramas which garnered the attention of the industry and users alike, further bolstering the Company’s brand influence. iQIYI also launched several new variety shows this year such as Dimension Nova and Let’s Sacalaca as vertical content for targeted audiences.

At this year’s event, iQIYI adhered to its core values of universal participation. For instance, the Company enhanced user engagement by creating hashtag campaigns on Weibo before the event. Throughout the 48-hour online carnival, iQIYI delivered a feast of entertainment to the world, and showcased the variety and quality of its content in 2020 and some key trends of the year ahead.

View original content to download multimedia:http://www.prnewswire.com/news-releases/iqiyi-showcases-strong-year-at-scream-night-2021-gala-event-301190129.html

SOURCE iQIYI, Inc.

The company is set to open a therapeutic health and training center in Kelowna, British
Columbia in May of 2021 

VANCOUVER, BC, Dec. 10, 2020 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (DTC: MCURF) (“Mind Cure” or the “Company”) is pleased today to announce its plans to open the first Mind Cure Health Center, which will offer psychedelic-assisted mental health therapy to patients as well as training to therapists. Located in Kelowna, British Columbia, the center is scheduled to open in May of 2021, and will offer patients access to therapeutic treatments with ketamine and psilocybin through utilizing Section 56 Exemptions, a legal exemption to Canadian drug laws granted by Health Canada.

“We have always seen our business as caring for individual mental health and wellness on a spectrum, from those who are suffering and are in need of relief to those who are looking for enhanced clarity, focus and overall well-being,” said Mind Cure President and CEO Kelsey Ramsden.

Mind Cure’s first Health Center will enable treatment and study of psychedelic-assisted therapy with personalized and technology enabled care, supporting individuals before, during and after treatment. The Kelowna location will offer eight treatment rooms and will serve a very important role to Mind Cure beyond its therapeutic opportunities. “This first Mind Cure Health Center will also act as a training hub as we advance our training model for therapists who want to offer psychedelic-assisted therapy in their clinics, or who want to better understand the care offered by Mind Cure so that they can feel confident referring patients,” continued Ramsden.

Mind Cure believes that a number of people seeking psychedelic-assisted therapy are not just those seeking relief from depression, migraines, and physical and psychological pain, but also individuals following the lead of executives, first from Silicon Valley and now, around the world, who have been looking to enhance their holistic wellness plans and productivity utilizing these therapeutic experiences. “Kelowna is a logical first location for a Mind Cure Health Center, both because of its proximity to Vancouver and Calgary, International Airports, as well as its growing local population and reputation as a destination city,” said Ramsden.

Mind Cure announced earlier this week that it is initiating its translational research program, focused on psilocybin, ketamine and ibogaine. The first two psychoactive compounds, psilocybin and ketamine, will be the first offered at the Health Center. Mind Cure also plans on rolling out an experience driven by technology for both therapists and patients, to enhance treatment potential and improve post-therapy integration and patient outcomes.

The Company has granted a total of 200,000 stock options to certain employees pursuant to the terms of the Company’s incentive stock option plan (the “Plan”).  The stock options are exercisable at a price of $0.65 and subject to the terms of the Plan.

About Mind Cure Health Inc.

Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care. 

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Philip Tapley, Chairman
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mind Cure opening its first Health Center in Kelowna, BC; Mind Cure receiving a Section 56 Exemption from Health Canada; Mind Cure offering treatments starting with ketamine and psilocybin, Mind Cure enabling the treatment and study of psychedelic-assisted therapy; Mind Cure’s Health Center acting as a training hub for therapists.

Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian and global economy and Mind Cure’s business, and the extent and duration of such impact; Mind Cure being able to open its Health Center; Mind Cure receiving a Section 56 Exemption from Health Canada; that people are seeking psychedelic-assisted therapy for both mental health as well as holistic wellness reasons. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian and global economy, Mind Cure’s industry and its business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect its investments, results of operations, financial condition and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; Mind Cure not being able to open its Health Center; and Mind Cure not receiving a Section 56 Exemption from Health Canada. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory

The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/mind-cure-moves-into-psychedelic-assisted-therapy-with-british-columbia-location-offering-ketamine-and-psilocybin-therapy-301189952.html

SOURCE Mind Cure Health Inc.

SINGAPORE, Dec. 10, 2020 /PRNewswire/ — S&P Global Platts (“Platts”), the leading independent provider of information and benchmark prices for the commodities and energy markets, announced today that its West India Marker (WIM) price assessment has been used as the settlement price for the first ever futures contract trade reported for LNG sold into the Indian market. The financially settled derivative contract was traded between Glencore and Total and brokered by Tullett Prebon.

Dominic Gallagher, Head of LNG Broking, Tullett Prebon, said: “We are proud to be involved in the first WIM futures contract trade, which has been settled against the Platts price. As the LNG market continues towards commoditisation, products such as the WIM futures contract should aid in the provision of transparency, tradability and price discovery. Tullett Prebon continues to invest in the developing global gas market, where we see significant growth opportunities, and this product forms part of the LNG market’s evolution.”

The derivatives trade is dollar-denominated and will be financially settled against the February average of S&P Global Platts’ WIM LNG price assessment for spot physical cargoes of LNG delivered ex-ship (DES) into ports in India and the Middle East region. The trade was executed as a spread against the futures contract that financially settles against the Platts JKM price assessment; the predominant LNG benchmark derivative product. Platts WIM reflects cargoes of 1,000-1,150 Btu/scf calorific value, of 3.2 million MMBtu volume, of vessel size range of 135,000-175,000m3 for delivery into India, Dubai and Kuwait.

The fast commoditization of LNG has resulted in the establishment of LNG benchmarks across different regions. The rapid development of WIM reflects a significant growth in transparency, standardization and liquidity of the LNG cargo trade in the Middle East and India region. LNG is forecast to become a key component of India’s gas consumption as the government increases its share of the energy mix. The Platts WIM provides the link between the global LNG market and the value of gas further downstream in India, as well as the anchor for the trading of spot LNG cargoes in South and West Asia.

Vera Blei, Head of Oil and LNG Market Pricing, S&P Global Platts, said: “This deal is a significant step towards the emergence of a new regional derivatives market for LNG delivered into the India and Middle East region. In spite of its size, this major trading region does not have a dedicated derivatives market reflecting its own supply and demand dynamics meaning physical market participants wishing to hedge can be exposed to significant basis risk.”

S&P Global Platts does not sponsor, endorse, promote or sell third party contracts or financial products.

Media Contacts:

Americas: Kathleen Tanzy + 1  917-331-4607, [email protected]

About S&P Global Platts
At S&P Global Platts, we provide the insights; you make better informed trading and business decisions with confidence. We’re the leading independent provider of information and benchmark prices for the commodities and energy markets. Customers in over 150 countries look to our expertise in news, pricing and analytics to deliver greater transparency and efficiency to markets. S&P Global Platts coverage includes oil, gas, LNG, power, petrochemicals, metals, agriculture and shipping.

S&P Global Platts is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies and governments to make decisions with confidence. For more information, visit www.platts.com.

About Glencore
Glencore is one of the world’s largest global diversified natural resource companies and a major producer and marketer of more than 60 commodities. The Group’s operations comprise around 150 mining and metallurgical sites and oil production assets.

With a strong footprint in over 35 countries in both established and emerging regions for natural resources, Glencore’s industrial activities are supported by its global marketing network.

Glencore’s customers are industrial consumers, such as those in the automotive, steel, power generation, battery manufacturing and oil sectors. We also provide financing, logistics and other services to producers and consumers of commodities. Glencore’s companies employ around 160,000 people, including contractors.

Glencore is proud to be a member of the Voluntary Principles on Security and Human Rights and the International Council on Mining and Metals. We are an active participant in the Extractive Industries Transparency Initiative.

About Total
Total is a broad energy company that produces and markets fuels, natural gas and electricity. Our 100,000 employees are committed to better energy that is more affordable, more reliable, cleaner and accessible to as many people as possible. Active in more than 130 countries, our ambition is to become the responsible energy major.

About TP ICAP
TP ICAP is a global firm of professional intermediaries that plays a pivotal role in the world’s financial, energy and commodities markets. Operating through our core businesses, Tullett Prebon, ICAP, PVM, Coex Partners, Tullett Prebon Information, ICAP Information Services and PVM Data Services, we create strong networks in person and through technology. We provide comprehensive analysis and insight into market conditions and long-term trends. We combine data, knowledge and intelligence into contextual insight and commercial guidance. By engaging with our clients, and providing innovative products and services, we enable our clients to transact with confidence, facilitating the flow of capital and commodities around the world, enhancing investment and contributing to economic growth. Our values of honesty, integrity, respect and excellence underpin everything we do.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/first-lng-futures-contract-traded-against-the-sp-global-platts-west-india-marker-301190105.html

SOURCE S&P Global Platts